Symbol | Exchange | Currency | ||
|---|---|---|---|---|
| NYSE | USD | Real-time | ||
| Mexico | MXN | Delayed | ||
| Stockholm | SEK | Real-time | ||
| Frankfurt | EUR | Delayed | ||
| TradeGate | EUR | Delayed | ||
| Hamburg | EUR | Delayed | ||
| Xetra | EUR | Delayed | ||
| Santiago | USD | Delayed | ||
| Buenos Aires | ARS | Delayed | ||
| BM&FBovespa | BRL | Delayed | ||
| Vienna | EUR | Delayed | ||
| KASE | USD | Delayed | ||
| Colombia | COP | Delayed | ||
| Lima | USD | Delayed |
By Bernard Orr and Martin Quin Pollard BEIJING (Reuters) - The number of COVID patients needing critical care in China's hospitals has peaked, health authorities said on Thursday,...
By Sophie Yu and Martin Quin Pollard BEIJING (Reuters) -When Li's 83-year-old father with diabetes started coughing and complaining of body aches last month, the Beijing resident...
By Davit Kirakosyan Pfizer (NYSE:PFE) shares closed more than 3% lower today after Wells Fargo downgraded the company to Equal Weight from Overweight and cut its price target to...
Drugmaker Merck's (NYSE:MRK) stock has outperformed its competitors year to date (ytd), rising 30.6%. Pfizer (NYSE:PFE), which I am bearish on, is down 16.9% so far this year. The...
Pfizer (NYSE:PFE) faces a $16 to $18 billion loss in revenue from 2025 through 2030 as it loses essential patents on five drugs.The drugs account for 40% of the company's Q3...
It remains difficult to bet against J&J in the long term Near-term challenges around currency and inflation will linger into 2023 Investors probably shouldn’t rush to...
Pfizer Inc. is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products around the world. The Company operations through two segments: Biopharma and PC1. Biopharma is a science-based medicines business that includes six therapeutic areas, such as Vaccines, Hospital, Oncology, Internal Medicine, Rare Disease, and Inflammation & Immunology. PC1 is its global contract development and manufacturing organization and supplier of specialty active pharmaceutical ingredients. Its Vaccines include Comirnaty/BNT162b2, the Prevnar family, Nimenrix and others. Its Oncology products include Ibrance, Xtandi, Inlyta, Sutent, Retacrit, Lorbrena and Braftovi. Its Internal Medicine products include Eliquis and the Premarin family. Its Inflammation & Immunology products include Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis and Cibinqo. It also offers Rimegepant and Zavegepant.
| Average | 53.97 (+19.93% Upside) |
| High | 75.00 |
| Low | 44.00 |
| Price | 45.00 |
| No. of Analysts | 24 |
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Strong Sell | Strong Sell | Strong Sell | Strong Sell | Neutral |
| Technical Indicators | Strong Sell | Strong Sell | Strong Sell | Strong Sell | Sell |
| Summary | Strong Sell | Strong Sell | Strong Sell | Strong Sell | Neutral |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 235.81 | 242.38 | 235.52 | -4.54 | -1.89% | 29.47M | NASDAQ | |||
| 28.81 | 29.82 | 28.63 | -0.79 | -2.67% | 43.01M | NASDAQ | |||
| 53.45 | 57.61 | 53.13 | -1.41 | -2.57% | 8.37M | NYSE | |||
| 12.41 | 12.85 | 12.40 | -0.26 | -2.05% | 48.50M | NYSE | |||
| 53.70 | 54.00 | 53.70 | 0.00 | 0.00% | 0.00 | NYSE | |||
| 135.19 | 138.61 | 135.03 | -0.75 | -0.55% | 68.70M | NASDAQ | |||
| 128.78 | 136.68 | 127.01 | -2.71 | -2.06% | 194.22M | NASDAQ | |||
| 652.29 | 676.11 | 651.54 | -5.90 | -0.90% | 1.15M | NASDAQ | |||
| 45.98 | 47.40 | 45.96 | -0.79 | -1.69% | 3.42M | NASDAQ | |||
| 326.33 | 330.08 | 321.25 | +0.11 | +0.03% | 7.76M | NASDAQ | |||
| 46.90 | 48.27 | 46.89 | -1.18 | -2.45% | 19.85M | NASDAQ | |||
| 177.23 | 182.38 | 176.94 | -3.26 | -1.81% | 8.89M | NYSE | |||
| 113.22 | 116.75 | 113.04 | -1.97 | -1.71% | 15.29M | NYSE | |||
| 233.97 | 239.85 | 233.70 | -2.73 | -1.15% | 349.54K | NYSE | |||
| 22.13 | 23.97 | 21.75 | -1.15 | -4.94% | 406.66K | NASDAQ |